Lundbeck to acquire Prexton Therapeutics
20.03.2018
Share this article
This acquisition will add foliglurax in clinical phase II to its pipeline of innovative treatments for patients suffering from Parkinson’s disease
Attachment
Attachment
Lundbeck announced on 16 March 2018 that it will acquire Prexton Therapeutics for up to EUR 905 million.